DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2017/0095531 A1 SCHREBER Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2017/0095531 A1 SCHREBER Et Al US 201700.95531A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0095531 A1 SCHREBER et al. (43) Pub. Date: Apr. 6, 2017 (54) COMPOSITIONS AND METHODS FOR on Dec. 4, 2015, provisional application No. 62/235, ADONING TYPE AND TYPE II 727, filed on Oct. 1, 2015. EXTRACELLULAR DOMAINSAS HETEROLOGOUS CHMERIC PROTEINS Publication Classification (71) Applicant: Heat Biologics, Inc., Durham, NC (US) (51) Int. Cl. A638/17 (2006.01) (72) Inventors: Taylor SCHREIBER, Durham, NC (52) U.S. Cl. (US); George FROMM, Durham, NC CPC ........ A6IK 38/1774 (2013.01); A61K 38/177 (US); Suresh DE SILVA, Durham, NC (2013.01) (US); Neal SCHILLING, Durham, NC (US) (57) ABSTRACT (21) Appl. No.: 15/281,196 The present invention relates to, interalia, compositions and methods, including chimeric proteins that find use in the (22) Filed: Sep. 30, 2016 treatment of disease. Such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various Related U.S. Application Data embodiments, fusions of extracellular domains of trans (60) Provisional application No. 62/372.574, filed on Aug. membrane proteins that can have stimulatory or inhibitory 9, 2016, provisional application No. 62/263.313, filed effects. Patent Application Publication Apr. 6, 2017 Sheet 1 of 41 US 2017/0095531A1 FGURE 1 ise 83 garag ise Eisenaries sister ce FIGURE 2 Patent Application Publication Apr. 6, 2017 Sheet 2 of 41 US 2017/0095531A1 FGURE 3 is Metab:re Festigierre cks esses - FIGURE 4 3888 88 Patent Application Publication Apr. 6, 2017 Sheet 3 of 41 US 2017/0095531A1 FGURE 5 2233 5 OOOO 1 5 O mPD1-FC nPO-FC-OX40 Patent Application Publication Apr. 6, 2017 Sheet 4 of 41 US 2017/0095531A1 FGURE 6 A. B. nP-Fc-OX40 l 3.50 300 & Media Control 2.50 & PD1-FC rt 2.00 8 nPD1-FC-OX40. l PD-Fc. Patent Application Publication Apr. 6, 2017. Sheet 5 of 41 US 2017/0095531A1 FGURE 7 8 mPD -FC-OX4OL PD-Fc-OX40 Patent Application Publication Apr. 6, 2017 Sheet 6 of 41 US 2017/0095531A1 FIGURE 8 10.0 8.0 6.O. an EP only 40 xxP) -FC-OX4OL 2.0 OO o 4 6 10 17 24 26 Days post-electroporation FIGURE 9 5 O 25 O asp only us-Pol-Fooxact O 6 1 17 20 Days post-electroporation Patent Application Publication Apr. 6, 2017 Sheet 7 of 41 US 2017/0095531A1 FIGURE 10 A. Mouse; PD1-Fc-ox404. B. 88: S.ww. 888s taggs: g . r 2000 OOO SO 253 Fc-bition rPD1-fc-OX40.(g/ml) Patent Application Publication Apr. 6, 2017 Sheet 8 of 41 US 2017/0095531A1 FIGURE 10 (continued) Activatedcate Primaryrimary Mouseviouse Spenocytes AT: (PO-11, F. 1.4 PC. .98% .9% E. 93.5% s s 2. s: s kis S. 10 8-X. g E FSocie: s g 8 s 1 * * to 8 is? * 33 6 Po-lice:s PO-3. Cells 6 ofEE population ing -> mP-3-APCas ais +3344; 3 cessceis +500g-FR) FP; k +38.30sis.F.C. cells i-FP--SGorg FP) *-i-4 ce's 45ts FP * +338.50 ccs --Stig FP} Patent Application Publication Apr. 6, 2017 Sheet 9 of 41 US 2017/0095531A1 FIGURE 11 A. MC38 Tumor rowth 2. an intreated crys? x tox40 (n:5) s P- (-5) GK4 fee)- n:5) x rinfl-Fc-CX40L naS} - - - - - - - - - - - - - - - - - - - - - - - - - - - --. OP-2 s ::first Session. 2. rete: 9:7: s :cox43. 35: : :Sc-X30s: ; Secondary Tumor intreated 2 neS 0. (OXAG 2 ho3) SS QP-2 (rs1 cQX40ACP.L. 2 (nies -a, / x mPD-Fc-QX40.2 in-4) :28:Fiasraelection : 50 mPDitc-OX40L 2. s 1. 5 25 3. 35 4. as 5 55 O 65 Days Postumor inocutation Patent Application Publication Apr. 6, 2017. Sheet 10 of 41 US 2017/0095531 A1 FIGURE 11 (continued) Periphera Blood B. C. Flow Cytometry D. Serum Cytokines Ox: an sNFy SO É4 s Os S so s s NF 90s C 203 O 5 & S. 2 25, 38, 35.30 45 5 33 SO 85 Days Post Tumor inoculation Patent Application Publication Apr. 6, 2017. Sheet 11 of 41 US 2017/0095531 A1 FIGURE 11 (continued) E, 80 or Size G, Memory Phenotyping on Day 13 Splenocytes Bay i3 Kics 2ks cks arra 8 sternary Prea; or s Shr-e Eter Mentory ce: 60 5 a 40 5 : 3. 8. s 2 is. S x s & & 8.8 s is pK. s exes & 3. F. .3 trate CD4 f CD8 Ratio ina Muttipley Tissues to 8treated ld Day 33 Peripheral Blood Speers 8 mPD1-fc-OX40t S. s say 2. day 3 3. E, 8 mPD1-Fe-GTR. i. w CB2a....O. a. ...OX43 3 *: C-3 d 2 & 53 S 3 2 8 Patent Application Publication Apr. 6, 2017 Sheet 12 of 41 FIGURE 11 (continued) C2S: Co. Cacer Day A. 3. x sox C2 tutor 1. Sess 8jection cytosines (S^0 ces {3 g) A natysis J. id: cytokine-P -o-> Cytokine-PE MoMo Patent Application Publication Apr. 6, 2017. Sheet 13 of 41 US 2017/0095531 A1 FIGURE t (continued) w X axe w xx 3:2 8 8 3 : 8 3 S & 3.8 s S as 'cs stics inciatio 3. i s S is . & S 3 & S & 3 as stor sociats Patent Application Publication US 2017/0095531A1 Patent Application Publication Apr. 6, 2017. Sheet 15 of 41 US 2017/0095531 A1 FIGURE3 A. B, Overlay from Thermo prep i&isig: ...ESA 3. cÉing: 3. 838ss ce E.35.& 8::c:::::: 8:12 ote 8ackgroufti Background fastic: 88c.gif a. s.3 k3 Patent Application Publication Apr. 6, 2017. Sheet 16 of 41 US 2017/0095531 A1 FIGURE 13 (continued) C f & CX43-is 3888-is 8,8. OX40-His 8.8 w8 .3 C 94 SL-279252 m 3.3 was 3888-FS3:3: 8 S232S2 . 8. i. TT's a 10,383 - Fic-Riitic hi-fc-X4Qingfin Patent Application Publication Apr. 6, 2017. Sheet 17 of 41 US 2017/0095531A1 FGRE 14 A. Binding to PE-3 B. Sinding to PD-2 C. Binding to OX40 38 : we'PE.Fcept. Crit 250.sy 8. :asio-fc Citi 2sory; x wS-2922 S.C. rhi S-2733S. 230 & 8 s g i. s c -Sswarara S 50 SSO -250 2SO 58 SS -250 25 5. SO time seconds Eime issconds: Eime seconds , Binding to FcR1A E. Binding to FcRn ka K K S. : S9. Sarpe: orate;iffs): (strate; fs; birding:y: k as a SEE 8.32 25 g 400 g 3 : 3.33E-S 837 E. SS s:g 300 g33. Cat: {500 & g soo. S.g33. Cat S.O.M3 P3: Ec & S-2792.52 SfR::M $3:33.25on 8 s 290 S 3. 23 as w3. Y s u 20 433 *x. -28 a8 is -3 Time seconds ite seconds Patent Application Publication Apr. 6, 2017. Sheet 18 of 41 US 2017/0095531 A1 FIGURE 14 (continued) G. Binding to PD-1 hi. Binding to PD-2 i. Binding to OX40 SOO as solic Cit}(338.8 8. as PI3-fc.cnt: 325 na: 58 ex40.-Fi: Cat 825 fsw / & co-3-cr-CX43. 2S: n, :... cop-cR-X40: 253 M3 : co-fcRii-OX42S,3 33 2 8 asyaraas s 250 S3 73 25 253 388 f -2S 350 s 75 Tirse (seconds: ine secords Eime seconds) As a s KS . Binding58 to FcR1A K. S.Binding s to FcRn2 -- san fe: tort-rate::fits off-rate::1fs: th:riting; it : an igg: inti{SOCniv.; S. w.... $ 400 3. Wi-FR-S.ision 3 : : e in g SO to iggs: cryi (5083 ; : ce:Fisk-F8-x4. ''::: & s 200 {s0} n S. as : sigs: 30.4....yw -23 20 --- c -2. 2 4. s Tina seconds fine seconds} Patent Application Publication Apr. 6, 2017. Sheet 19 of 41 US 2017/0095531A1 W O art trar 38 4. w Xenograft. Histology 838-y:ce:388 s Serum taif-life (EISA \ age 2: P.S.to hrs FC Capture 13.8 hrs (K45 Capture sons: F. SSA &3-8:a: Fi . E. C 8. S. 3 is time hours N. intraturoraihai-life Flow Cytometry Haifa e. pt-33 33 -N : - \, 3 20 - Vs - i a. & A. SS-PO-1wPE-3. .e38,Csis R. 38 R. 338 28S fine hours Patent Application Publication Apr. 6, 2017. Sheet 20 of 41 US 2017/0095531 A1 FIGURE 5 Celi Line Development to Test in Vitro Fusion Protein Binding Jurkat Parentat 0.83% CHO-K1 Parental 0.77% CHO-K1 Parentai 0.86% x JurkatfhoX40 96.8% Ho-KafhpD-, 97.4% : CHO-Ki?hCD47 72.4% 18p 3 O or "r OX40-APCw- D--APCsa). CD4-AC web Patent Application Publication Apr. 6, 2017 Sheet 21 of 41 US 2017/0095531A1 FIGURE 15 (continued) hPD-Fc-OX40L isotype contral x g A. as 250 rig i as C-K. Parents 62.5 g. g & CHO-Ki?h-l. 3. a ac a s s s S.g a cy as ea Shes t KO-APC re E aircast Pass -x-girkat{OX40 & g OXA-APCM Patent Application Publication Apr. 6, 2017. Sheet 22 of 41 US 2017/0095531 A1 FIGURE 15 (continued) Cia-C-OX4, , & Esotsie Cott: an - 3 & -- Cis-X:3:? s o 3 •r 3. BX3-8aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa-h gfi. 3. aspairst $3 ea: 8. -x skat{X4 r recreer 8 884. A w. giffiti. Patent Application Publication Apr. 6, 2017. Sheet 23 of 41 US 2017/0095531 A1 FIGURE 15 (continued) Human S-2792.52 Binding in vitro to PB-1 Expressing Celis ..
Load more

Recommended publications
  • Calreticulin—Multifunctional Chaperone in Immunogenic Cell Death: Potential Significance As a Prognostic Biomarker in Ovarian
    cells Review Calreticulin—Multifunctional Chaperone in Immunogenic Cell Death: Potential Significance as a Prognostic Biomarker in Ovarian Cancer Patients Michal Kielbik *, Izabela Szulc-Kielbik and Magdalena Klink Institute of Medical Biology, Polish Academy of Sciences, 106 Lodowa Str., 93-232 Lodz, Poland; [email protected] (I.S.-K.); [email protected] (M.K.) * Correspondence: [email protected]; Tel.: +48-42-27-23-636 Abstract: Immunogenic cell death (ICD) is a type of death, which has the hallmarks of necroptosis and apoptosis, and is best characterized in malignant diseases. Chemotherapeutics, radiotherapy and photodynamic therapy induce intracellular stress response pathways in tumor cells, leading to a secretion of various factors belonging to a family of damage-associated molecular patterns molecules, capable of inducing the adaptive immune response. One of them is calreticulin (CRT), an endoplasmic reticulum-associated chaperone. Its presence on the surface of dying tumor cells serves as an “eat me” signal for antigen presenting cells (APC). Engulfment of tumor cells by APCs results in the presentation of tumor’s antigens to cytotoxic T-cells and production of cytokines/chemokines, which activate immune cells responsible for tumor cells killing. Thus, the development of ICD and the expression of CRT can help standard therapy to eradicate tumor cells. Here, we review the physiological functions of CRT and its involvement in the ICD appearance in malignant dis- ease. Moreover, we also focus on the ability of various anti-cancer drugs to induce expression of surface CRT on ovarian cancer cells. The second aim of this work is to discuss and summarize the prognostic/predictive value of CRT in ovarian cancer patients.
    [Show full text]
  • Immunopharmacology
    Institute of Pharmacology http://www.pki.unibe.ch/ PKI Immunopharmacology Prof. Dr. Stephan von Gunten MD PhD MME Lectures: Clinical Immunology Immunomodulation Endogenous or exogenous molecules that influence immune responses positively (immunostimulation) or negatively (immunoregulation) DC Based Vaccination Freund complete adjuvans (FCA) Freund incomplete adjuvans (FIA) (mycobacteria + mineral oils) (mineral oils, without mycobacteria) differential maturation alum (hydrated alumina) dendritic cell (DC) mycobacteria Toll-like Receptors alum, mineral NLR-Inflammasome oils in FCA/FIA Toll-Like Receptors PAMPs 2 major adapters: MyD88 and TRIF protein kinases transcription factor (NFkB, IRF-3/-7) [IRF: Interferon regulatory factor] gene transcription: inflammatory cytokines, IFNa/b, others BMSc Pharma Immuno Manicassamy S & Pulendran B, Seminars in Immunology 2009 (modified) TLR Agonists and Cancer Immunotherapy: BCG-CWS BCG: Bacillus Calmette-Guérin, attenuated form of Mycobacterium bovis CWS (cell-wall skeleton ): major adjuvant–active part of mycobacterial cells; contains muramyldipeptide (MDP) -> activation of TLR-2 and -4 and NOD2 BCG-CWS TLR-2 MyD88-pathway mDC cytokines CTL tumour cell killing Carbohydrate-based vaccines in development Infectious disease Infectious Cancer Astronomo RD & Burton DR Nat Rev Drug Discov 2016 (modified) Antibody repertoire: glycan immunogenicity linked to structure Schneider et al. Sci Transl Med 2015 Cancer Immunotherapy Galluzi L et al. Oncotarget 2014 Siglec expression on immune cells Jandus C et al. Biochem Pharmacol 2011 Illustration by Aldona von Gunten The sialoglycan shield Jandus C & Boligan KF et al. J Clin Invest. 2014 Siglecs on CD8 T cells? May 2019 Cover Story American Association of Cancer Research (AACR) Immunomodulation Endogenous or exogenous molecules that influence immune responses positively (immunostimulation) or negatively (immunoregulation) Antiinflammatory vs.
    [Show full text]
  • The Immunophilins, Fk506 Binding Protein and Cyclophilin, Are Discretely Localized in the Brain: Relationship to Calcineurin
    NeuroscienceVol. 62,NO. 2, pp. 569-580,1994 Elsevier Sctence Ltd Copyright 0 1994 IBRO Pergamon 0306-4522(94)E0182-4 Printed in Great Britain. All rights reserved 0306-4522194 $7.00 + 0.00 THE IMMUNOPHILINS, FK506 BINDING PROTEIN AND CYCLOPHILIN, ARE DISCRETELY LOCALIZED IN THE BRAIN: RELATIONSHIP TO CALCINEURIN T. M. DAWSON,*t J. P. STEINER,* W. E. LYONS,*11 M. FOTUHI,* M. BLUE? and S. H. SNYDER*f§l Departments of *Neuroscience, tNeurology, $Pharmacology and Molecular Sciences, and §Psychiatry, Johns Hopkins University School of Medicine, 725 N. Wolfe Street, Baltimore, MD 21205, U.S.A. (IDivision of Toxicological Science, Johns Hopkins University School of Hygiene and Public Health Abstract-The immunosuppressant drugs cyclosporin A and FK506 bind to small, predominantly soluble proteins cyclophilin and FK506 binding protein, respectively, to mediate their pharmacological actions. The immunosuppressant actions of these drugs occur through binding of cyclophilin-cyclosporinA and FK506 binding protein-FK506 complexes to the calcium-calmodulin-dependent protein phosphatase, calcineurin, inhibiting phosphatase activity, Utilizing immunohistcchemistry, in situ hybridization and autoradiography, we have localized protein and messenger RNA for FKS06 binding protein, cyclophilin and calcineurin. All three proteins and/or messages exhibit a heterogenous distribution through the brain and spinal cord, with the majority of the localizations being neuronal. We observe a striking co-localiz- ation of FK506 binding protein and calcineurin in most
    [Show full text]
  • TLR-Mediated Activation Pathways Calcineurin Negatively Regulates
    Calcineurin Negatively Regulates TLR-Mediated Activation Pathways Young Jun Kang, Brenda Kusler, Motoyuki Otsuka, Michael Hughes, Nobutaka Suzuki, Shinobu Suzuki, Wen-Chen Yeh, This information is current as Shizuo Akira, Jiahuai Han and Patricia P. Jones of September 26, 2021. J Immunol 2007; 179:4598-4607; ; doi: 10.4049/jimmunol.179.7.4598 http://www.jimmunol.org/content/179/7/4598 Downloaded from References This article cites 61 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/179/7/4598.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Calcineurin Negatively Regulates TLR-Mediated Activation Pathways1 Young Jun Kang,2,3* Brenda Kusler,* Motoyuki Otsuka,† Michael Hughes,* Nobutaka Suzuki,‡ Shinobu Suzuki,‡ Wen-Chen Yeh,‡ Shizuo Akira,§ Jiahuai Han,† and Patricia P.
    [Show full text]
  • How HIV-1 Gag Manipulates Its Host Cell Proteins: a Focus on Interactors of the Nucleocapsid Domain
    viruses Review How HIV-1 Gag Manipulates Its Host Cell Proteins: A Focus on Interactors of the Nucleocapsid Domain 1 2, 2, 2 1 Jéromine Klingler , Halina Anton y, Eléonore Réal y, Manon Zeiger , Christiane Moog , Yves Mély 2 and Emmanuel Boutant 2,* 1 INSERM UMR_S 1109, Centre de Recherche en Immunologie et Hématologie, Faculté de Médecine, Université de Strasbourg, 67000 Strasbourg, France; [email protected] (J.K.); [email protected] (C.M.) 2 UMR 7021, CNRS, Laboratoire de Bioimagerie et Pathologies, Université de Strasbourg, Faculté de Pharmacie, 67400 Illkirch, France; [email protected] (H.A.); [email protected] (E.R.); [email protected] (M.Z.); [email protected] (Y.M.) * Correspondence: [email protected] These authors contributed equally to this work. y Received: 13 July 2020; Accepted: 10 August 2020; Published: 13 August 2020 Abstract: The human immunodeficiency virus (HIV-1) polyprotein Gag (Group-specific antigen) plays a central role in controlling the late phase of the viral lifecycle. Considered to be only a scaffolding protein for a long time, the structural protein Gag plays determinate and specific roles in HIV-1 replication. Indeed, via its different domains, Gag orchestrates the specific encapsidation of the genomic RNA, drives the formation of the viral particle by its auto-assembly (multimerization), binds multiple viral proteins, and interacts with a large number of cellular proteins that are needed for its functions from its translation location to the plasma membrane, where newly formed virions are released. Here, we review the interactions between HIV-1 Gag and 66 cellular proteins.
    [Show full text]
  • B-Cell Activation by Crosslinking of Surface Igm Or Ligation of CD40 Involves Alternative Signal Pathways and Results in Different B-Cell Phenotypes HENRY H
    Proc. Natl. Acad. Sci. USA Vol. 92, pp. 3348-3352, April 1995 Immunology B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes HENRY H. WORTIS*t, MARK TEUTSCH*, MINDY HIGER*, JENNY ZHENG*, AND DAVID C. PARKERt§ *Department of Pathology, Tufts University School of Medicine, and Graduate Program in Immunology, Sackler School of Graduate Biomedical Sciences, Boston, MA 02111; and tDepartment of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Worcester, MA 01655 Communicated by Salome G. Waelsch, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY December 7, 1994 ABSTRACT Treatment of small resting B cells with sol- direct contact with an activated T-helper cell such that the uble F(ab')2 fragments of anti-IgM, an analogue of T-inde- surface molecule gp39 [CD40 ligand (CD40L)] of the T cell pendent type 2 antigens, induced activation characterized by ligates the CD40 of the B cell (10). proliferation and the expression of surface CD5. In contrast, Our strategy to determine if minimal TD and TI-2 signals B cells induced to proliferate in response to thymus-dependent were sufficient to induce phenotypic differences in B cells was inductive signals provided by either fixed activated T-helper 2 to use an antigen that could be modified so as to initiate either cells or soluble CD40 ligand-CD8 (CD40L) recombinant pro- a TD or a TI-2 response. To produce a TD response we used tein displayed elevated levels of CD23 (FcJII receptor) and no monovalent Fab of rabbit anti-IgM and provided help in the surface CD5.
    [Show full text]
  • Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects
    Journal of Immunology Research Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects Guest Editors: Roberta Castriconi, Barbara Savoldo, Daniel Olive, and Fabio Pastorino Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects Journal of Immunology Research Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects Guest Editors: Roberta Castriconi, Barbara Savoldo, Daniel Olive, and Fabio Pastorino Copyright © 2016 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “Journal of Immunology Research.” All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board B. D. Akanmori, Congo Eung-Jun Im, USA G. Opdenakker, Belgium Stuart Berzins, Australia Hidetoshi Inoko, Japan Luigina Romani, Italy Kurt Blaser, Switzerland Peirong Jiao, China Aurelia Rughetti, Italy Federico Bussolino, Italy Taro Kawai, Japan Takami Sato, USA N. G. Chakraborty, USA Hiroshi Kiyono, Japan Senthamil Selvan, USA Robert B. Clark, USA Shigeo Koido, Japan Naohiro Seo, Japan Mario Clerici, Italy Herbert K. Lyerly, USA Ethan M. Shevach, USA Nathalie Cools, Belgium Enrico Maggi, Italy George B. Stefano, USA Mark J. Dobrzanski, USA Mahboobeh Mahdavinia, USA T. J. Stewart, Australia Nejat K. Egilmez, USA Eiji Matsuura, Japan J. Tabarkiewicz, Poland Eyad Elkord, UK C. J. M. Melief, The Netherlands Ban-Hock Toh, Australia S. E. Finkelstein, USA Chikao Morimoto, Japan Joseph F. Urban, USA Luca Gattinoni, USA Hiroshi Nakajima, Japan Xiao-Feng Yang, USA David E. Gilham, UK Toshinori Nakayama, Japan Qiang Zhang, USA Douglas C.
    [Show full text]
  • Toll-Like Receptor–Mediated Induction of Type I Interferon in Plasmacytoid Dendritic Cells Requires the Rapamycin-Sensitive PI(3)K-Mtor-P70s6k Pathway
    ARTICLES Toll-like receptor–mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway Weiping Cao1, Santhakumar Manicassamy1, Hua Tang1, Sudhir Pai Kasturi1, Ali Pirani2, Niren Murthy3 & Bali Pulendran1,4 Robust production of type I interferon (IFN-a/b) in plasmacytoid dendritic cells (pDCs) is crucial for antiviral immunity. Here we show involvement of the mammalian target of rapamycin (mTOR) pathway in regulating interferon production by pDCs. Inhibition of mTOR or its ‘downstream’ mediators, the p70 ribosomal S6 protein kinases p70S6K1 and p70S6K2, during pDC activation http://www.nature.com/natureimmunology by Toll-like receptor 9 (TLR9) blocked the interaction of TLR9 with the adaptor MyD88 and subsequent activation of the interferon-regulatory factor IRF7, which resulted in impaired IFN-a/b production. Microarray analysis confirmed that inhibition of mTOR by the immunosuppressive drug rapamycin suppressed antiviral and anti-inflammatory gene expression. Consistent with this, targeting rapamycin-encapsulated microparticles to antigen-presenting cells in vivo resulted in less IFN-a/b production in response to CpG DNA or the yellow fever vaccine virus strain 17D. Thus, mTOR signaling is crucial in TLR-mediated IFN-a/b responses by pDCs. Plasmacytoid dendritic cells (pDCs) are specialized immune cells able or p70S6K by various approaches resulted in much less TLR-mediated to rapidly produce large amounts of type I interferon for antiviral production of interferon-a (IFN-a) by pDCs. The mechanism of this innate immunity1–3. Induction of the antiviral innate immune inhibition seemed to involve disruption of the TLR9-MyD88 complex Nature Publishing Group Group Nature Publishing 8 response depends on recognition of viral components by Toll-like and subsequent impairment of phosphorylation and nuclear translo- receptors (TLRs)4.
    [Show full text]
  • Two Distinct Signal Transmission Pathways in T Lymphocytes
    Proc. Natl. Acad. Sci. USA Vol. 87, pp. 9231-9235, December 1990 Immunology Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin (cyclosporin A/FK506 binding protein/rotamase) BARBARA E. BIERER*tf§, PETRI S. MATTILA¶, ROBERT F. STANDAERTII, LEONARD A. HERZENBERG$, STEVEN J. BURAKOFF*tt, GERALD CRABTREE¶, AND STUART L. SCHREIBERII *Division of Pediatric Oncology, Dana-Farber Cancer Institute; tHematology Division, Department of Medicine, Brigham & Women's Hospital; Departments of tMedicine and "tPediatrics, Harvard Medical School, Boston, MA 02115; TBeckman Center for Molecular and Genetic Medicine, Stanford University, Stanford, CA 94305; and I'Department of Chemistry, Harvard University, Cambridge, MA 02138 Communicated by Samuel J. Danishefsky, August 13, 1990 (received for review July 11, 1990) ABSTRACT Proliferation and immunologic function of T actions of these drugs. Our results suggest that a common lymphocytes are initiated by signals from the antigen receptor drug receptor binding site is involved in at least two distinct that are inhibited by the immunosuppressant FK506 but not by signaling pathways in the T-cell activation cascade. Both its structural analog, rapamycin. On the other hand, interleu- rapamycin (Kd = 0.2 nM) and FK506 (Kd = 0.4 nM) are kin 2 (IL-2)-induced signals are blocked by rapamycin but not shown to bind with high affinity to FKBP. Thus, FKBP is by FK506. Remarkably, these two drugs inhibit each other's possibly involved in one or both of the aforementioned actions, raising the possibility that both act by means of a pathways. In addition, both rapamycin (K, = 0.2 nM) and common immunophilin (immunosuppressant binding protein).
    [Show full text]
  • FKBP Family Proteins: Immunophilins with Versatile Biological Functions
    This document is downloaded from DR‑NTU (https://dr.ntu.edu.sg) Nanyang Technological University, Singapore. FKBP family proteins : immunophilins with versatile biological functions Kang, Cong Bao; Ye, Hong; Dhe‑Paganon, Sirano; Yoon, Ho Sup 2008 Kang, C. B., Ye, H., Dhe‑Paganon, S., & Yoon, H. S. (2008). FKBP family proteins : immunophilins with versatile biological functions. Neurosignals, 16(4), 318–325. https://hdl.handle.net/10356/95238 https://doi.org/10.1159/000123041 © 2008 S. Karger AG, Basel. This is the author created version of a work that has been peer reviewed and accepted for publication by Neurosignals, S. Karger AG, Basel. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: http://dx.doi.org/10.1159/000123041. Downloaded on 28 Sep 2021 01:49:48 SGT FKBP Family Proteins: Immunophilins with Versatile Biological Functions Cong Bao Kang a, Hong Ye a, Sirano Dhe-Paganon b, Ho Sup Yoon a,* a School of Biological Science, Nanyang Technological University, Singapore , Singapore; b Structural Genomics Consortium and Physiology, Banting Institute, University of Toronto, Toronto, Ont. , Canada * Tel. +65 6316 2846, Fax +65 6791 3856, E-Mail [email protected] Key Words Immunophilin • FK506-binding protein • Peptidylprolyl cis/trans isomerase • Immunophilin ligand • Neuroprotection • FK506 • Rapamycin Abstract Immunophilins consist of a family of highly conserved proteins binding with immunosuppressive drugs such as FK506, rapamycin and cyclosporin A. FK506-binding protein (FKBP) is one of two major immunophilins and most of FKBP family members bind FK506 and show peptidylprolyl cis/trans isomerase (PPIase) activity.
    [Show full text]
  • HLA-Derived Peptides Which Inhibit T Cell Function Bind to Members of the Heat-Shock Protein 70 Family by Elfriede N613ner, Jodi E
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central HLA-derived Peptides which Inhibit T Cell Function Bind to Members of the Heat-Shock Protein 70 Family By Elfriede N613ner, Jodi E. Goldberg,* Clarissa Naftzger, Shu-Chen Lyu,* Carol Clayberger,* and Alan M. Krensky From the Division of Immunology and Transplantation Biology/Department of Pediatrics and the *Department of Cardiothoracic Surgery, Stanford University, Stanford, California 94305 Summary Synthetic peptides corresponding to sequences of HLA class I molecules have inhibitory effects on T cell function. The peptides investigated in this study have sequences corresponding to the relatively conserved region of the or1 helix of HLA class I molecules that overlaps the "public epitope" Bw4/Bw6. These HLA-derived peptides exhibit inhibitory effects on T lymphocytes and have beneficial effects on the survival ofallogeneic organ transplants in mice and rats. Pep- tides corresponding to the Bw4a epitope appear most potent as they inhibit the differentiation of T cell precursors into mature cytotoxic T lymphocytes (CTL) and target cell lysis by estab- lished CTL lines and clones. To elucidate the mechanism through which these peptides medi- ate their inhibitory effect on T lymphocytes, peptide binding proteins were isolated from T cell lysates. We show that the inhibitory Bw4a peptide binds two members of the heat-shock pro- tein (HSP) 70 family, constitutively expressed HSC70 and heat-inducible HSP70. Peptide binding to HSC/HSP70 is sequence specific and follows the rules defined by the HSC70 bind- ing motif. Most intriguing, however, is the strict correlation of peptide binding to HSC/ HSP70 and the functional effects such that only inhibitory peptides bind to HSC70 and HSP70 whereas noninhibitory peptides do not bind.
    [Show full text]
  • Transplantation David Straus, Ph.D
    Transplantation David Straus, Ph.D. OBJECTIVES Understand the following: 1. The types of graft rejection 2. What are alloantigens 3. Basis for alloreactivity 4. The classes of immunosuppressive agents and how they work 5. Why a bone marrow transplant might be done, and the importance of HLA matching 6. Basis for Graft vs. Host disease 7. Problems associated with xenotransplantation REFERENCES Parham, P. Chapter 12 p. 391 - 412, 417-420 ABBREVIATIONS Human Leukocyte Antigen: HLA Major Histocompatibility Complex: MHC (mouse equivalent of HLA) T cell antigen receptor: TCR Antigen-presenting cell: APC Nuclear factor of activated T cells: NFAT Interleukin –2: IL-2 Cyclosporin A: CsA ARTICLE Bluestone, et.al. CTLA4Ig: Bridging the Basic Commentary Immunology with Clinical Application. Immunity 24, 233–238, March 2006 ª2006 Elsevier Inc. I. Introduction Transplantation of organs or tissues, to replace diseased or non-functional counterparts, has been a longstanding medical goal. Unfortunately, the immune system of the recipient usually acts as a barrier to successful transplantation. The transplanted tissue is recognized as foreign and rejected. Immunosuppressive drugs have greatly improved the outcome of transplantation procedures, though the goal of inducing tolerance to the transplanted tissue remains. Bone marrow transplantation has unique requirements for compatibility of the donor and host, and unique problems associated with the transfer of immune cells. In addition to immunity, the availability of organs for transplantation is a severe limiting factor. For this reason xenotransplantation is being explored as an option. II. Graft Rejection: Early transplant studies clearly indicated the importance of the genetic relatedness of the graft and recipient.
    [Show full text]